Overview

The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial

Status:
TERMINATED

Trial end date:
2025-01-29

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the efficacy, safety, tolerability and pharmacokinetic (PK) profile of prophylactic SerpinPC in participants with hemophilia

Phase:

PHASE3

Details

Lead Sponsor:

ApcinteX Ltd

Collaborator:

Centessa Pharmaceuticals plc

Treatments:

Protein C